Skip to content
Sevabertinib Approval Narrows HER2-Mutated NSCLC Use episode artwork

Sep 24, 2026 1 min

Sevabertinib Approval Narrows HER2-Mutated NSCLC Use

from TheBrief.Health Hosted by TheBrief.Health

FDA cleared Dexcom Stelo for over-the-counter use in people aged 2 years and older without insulin use, expanding access while leaving clinical outcomes uncertain.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Sevabertinib Approval Narrows HER2-Mutated NSCLC Use

0:00 1:37

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on September 24, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.